JP2020531002A - 獣医学用ｉｇｇ ｆｃ変異体 - Google Patents

獣医学用ｉｇｇ ｆｃ変異体 Download PDF

Info

Publication number
JP2020531002A
JP2020531002A JP2020507675A JP2020507675A JP2020531002A JP 2020531002 A JP2020531002 A JP 2020531002A JP 2020507675 A JP2020507675 A JP 2020507675A JP 2020507675 A JP2020507675 A JP 2020507675A JP 2020531002 A JP2020531002 A JP 2020531002A
Authority
JP
Japan
Prior art keywords
seq
polypeptide
amino acid
igg
acid substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020507675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531002A5 (cg-RX-API-DMAC7.html
Inventor
ハンチュン チャン，
ハンチュン チャン，
ラム グェン，
ラム グェン，
ヨンチョン リー，
ヨンチョン リー，
フォーン チエン，
フォーン チエン，
シー ジアン リー，
シー ジアン リー，
Original Assignee
キンドレッド バイオサイエンシズ インコーポレイテッド
キンドレッド バイオサイエンシズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65361820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2020531002(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by キンドレッド バイオサイエンシズ インコーポレイテッド, キンドレッド バイオサイエンシズ インコーポレイテッド filed Critical キンドレッド バイオサイエンシズ インコーポレイテッド
Publication of JP2020531002A publication Critical patent/JP2020531002A/ja
Publication of JP2020531002A5 publication Critical patent/JP2020531002A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2020507675A 2017-08-15 2018-08-15 獣医学用ｉｇｇ ｆｃ変異体 Pending JP2020531002A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762545858P 2017-08-15 2017-08-15
US62/545,858 2017-08-15
PCT/IB2018/056142 WO2019035010A1 (en) 2017-08-15 2018-08-15 IGG VARIANTS FOR VETERINARY USE

Publications (2)

Publication Number Publication Date
JP2020531002A true JP2020531002A (ja) 2020-11-05
JP2020531002A5 JP2020531002A5 (cg-RX-API-DMAC7.html) 2021-09-30

Family

ID=65361820

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020507675A Pending JP2020531002A (ja) 2017-08-15 2018-08-15 獣医学用ｉｇｇ ｆｃ変異体

Country Status (10)

Country Link
US (1) US12297272B2 (cg-RX-API-DMAC7.html)
EP (1) EP3668536A4 (cg-RX-API-DMAC7.html)
JP (1) JP2020531002A (cg-RX-API-DMAC7.html)
KR (1) KR20200057701A (cg-RX-API-DMAC7.html)
CN (2) CN111182915A (cg-RX-API-DMAC7.html)
AU (3) AU2018318440A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020002871A2 (cg-RX-API-DMAC7.html)
CA (1) CA3071337A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020001707A (cg-RX-API-DMAC7.html)
WO (1) WO2019035010A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024530036A (ja) * 2021-08-06 2024-08-14 ペットメディックス・リミテッド 抗体Ｆｃバリアント

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019011860A2 (pt) 2016-12-09 2019-11-12 Akston Biosciences Corp proteína de fusão insulina-fc, sequência de ácido nucleico recombinante que codifica a mesma, vetor, célula eucariótica modificada, kit e método para tratar ou prevenir o diabetes autoimune
WO2019035010A1 (en) 2017-08-15 2019-02-21 Kindred Biosciences, Inc. IGG VARIANTS FOR VETERINARY USE
SI4186920T1 (sl) 2018-06-29 2024-05-31 Akston Biosciences Corporation Ultra dolgo delujoči inzulin-FC fuzijski proteini in postopki uporabe
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
MX2021004313A (es) * 2018-10-18 2021-05-27 Kindred Biosciences Inc Variantes de fc con union alterada al receptor de fc neonatal (fcrn) para uso veterinario.
US20220064263A1 (en) * 2018-12-27 2022-03-03 Kindred Biosciences, Inc. IGG FC Variants for Veterinary Use
US11542333B2 (en) * 2019-01-03 2023-01-03 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
BR112021018156A2 (pt) * 2019-03-20 2021-11-16 Kindred Biosciences Inc Antagonistas de ngf para uso médico
EP4004035A4 (en) * 2019-07-30 2023-06-28 Kindred Biosciences, Inc. Parvovirus antibodies for veterinary use
CA3159486A1 (en) 2019-12-19 2021-06-24 Thomas M. Lancaster Ultra-long acting insulin-fc fusion proteins and methods of use
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
JP2023513952A (ja) 2020-02-19 2023-04-04 アディボ ゲーエムベーハー 改変Ｆｃ領域
WO2021188631A1 (en) * 2020-03-18 2021-09-23 Kindred Biosciences, Inc. Anti-il4 receptor antibodies for veterinary use
WO2021207599A1 (en) 2020-04-10 2021-10-14 Akston Biosciences Corporation Antigen specific immunotherapy for covid-19 fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
CA3173864A1 (en) * 2020-04-22 2021-10-28 Shyr Jiann Li Long-acting anti-il31 antibodies for veterinary use
GB202005879D0 (en) * 2020-04-22 2020-06-03 Petmedix Ltd Heterodimeric proteins
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
CN115867572B (zh) 2020-05-11 2025-06-06 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物和使用方法
EP4178977A1 (en) 2020-07-10 2023-05-17 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in felines and methods of use
US20230405150A1 (en) * 2020-08-24 2023-12-21 The Trustees Of The University Of Pennsylvania Viral vector encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases in felines
CN112625093B (zh) * 2020-12-29 2022-12-23 清远市图微安创科技开发有限公司 用于预防和/或治疗非酒精性脂肪肝炎的多肽化合物
EP4373861A4 (en) 2021-07-23 2025-08-20 Akston Biosciences Corp INSULIN-FC FUSION PROTEINS AND METHODS OF USE FOR TREATING CANCER
EP4642796A2 (en) 2022-12-27 2025-11-05 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
CN121002059A (zh) 2023-01-20 2025-11-21 因外泰克斯公司 用于伴侣动物的双特异性结合剂
GB202311984D0 (en) * 2023-08-04 2023-09-20 Petmedix Ltd Optimised fc molecules
WO2025166165A1 (en) * 2024-02-01 2025-08-07 Zoetis Services, Llc Compositions and methods for modifying antibody effector functions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090181912A1 (en) * 2005-07-27 2009-07-16 Qinghua Wang GLP/1/EXENDIN 4 IgG Fc FUSION CONSTRUCTS FOR TREATMENT OF DIABETES
JP2010533197A (ja) * 2007-07-10 2010-10-21 イーライ リリー アンド カンパニー ＧＬＰ−１−Ｆｃ融合タンパク質配合物
WO2016108654A1 (ko) * 2014-12-31 2016-07-07 주식회사 제넥신 Glp 및 면역글로불린 하이브리드 fc 융합 폴리펩타이드 및 이의 용도

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6207383B1 (en) * 1998-07-27 2001-03-27 University Of Utah Research Foundation Mutations in and genomic structure of HERG—a long QT syndrome gene
US7297482B2 (en) * 1998-10-08 2007-11-20 Rigel Pharmaceuticals, Inc. Structurally biased random peptide libraries based on different scaffolds
ATE480558T1 (de) * 1999-12-23 2010-09-15 Univ Geneve Auf scf peptid basiertes basolaterales sortiersignal und inhibitoren dafür
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
JP2004321100A (ja) 2003-04-25 2004-11-18 Rikogaku Shinkokai ＩｇＧのＦｃ領域を含むタンパク質の変異体
UA87458C2 (ru) 2003-06-12 2009-07-27 Елі Ліллі Енд Компані Гибридные белки-аналоги glp-1
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP1831252B1 (en) 2004-12-22 2009-07-01 Eli Lilly And Company Glp-1 analog fusion protein formulations
WO2006105062A2 (en) * 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
EP3318573A1 (en) * 2008-12-23 2018-05-09 F. Hoffmann-La Roche AG Mmunoglobulin variants with altered binding to protein a
WO2010117760A2 (en) 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Fusion proteins comprising canine fc portions
WO2010117448A2 (en) 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
JP2013523098A (ja) 2010-03-29 2013-06-17 ザイムワークス，インコーポレイテッド 強化又は抑制されたエフェクター機能を有する抗体
JP2013537416A (ja) 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
EP3590965A1 (en) 2011-03-29 2020-01-08 Roche Glycart AG Antibody fc variants
CA2835094C (en) 2011-05-06 2020-12-22 David Gearing Anti-nerve growth factor antibodies and methods of preparing and using the same
WO2012153123A1 (en) 2011-05-06 2012-11-15 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
EP2537864B1 (en) 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
CN103930134B (zh) 2011-07-18 2016-12-21 阿茨生物股份有限公司 长效促黄体激素(lh)化合物
AU2012285475B2 (en) 2011-07-19 2017-09-14 The National Institute For Biotechnology In The Negev, Ltd. Novel IL-17R-ECD mutants
BR112014010008A2 (en) 2011-10-26 2018-09-04 Novartis Ag monoclonal antibodies, their uses and nucleic acids
WO2013063702A1 (en) 2011-11-04 2013-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
HK1201541A1 (en) * 2012-02-22 2015-09-04 Nexvet Australia Pty Ltd Tumour necrosis factor receptor fusion proteins and methods of using the same
CA2871934C (en) 2012-04-30 2023-06-13 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
EP2880057A4 (en) 2012-08-02 2016-03-23 Jn Biosciences Llc MULTIMERIZED FUSION ANTIBODIES OR PROTEINS THROUGH THE MUTATION OF A CYSTEINE AND A PIECE OF TAIL
WO2014093387A1 (en) 2012-12-10 2014-06-19 Kindred Biosciences, Inc. Vegf receptor fusion proteins for veterinary use
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
KR20160034404A (ko) 2013-07-31 2016-03-29 암젠 인크 Ｆc-함유 폴리펩타이드의 안정화
EP3033355A1 (en) 2013-08-16 2016-06-22 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
AU2014368449C1 (en) 2013-12-20 2021-05-06 Intervet International B.V. Canine antibodies with modified CH2-CH3 sequences
EP3104887A4 (en) 2014-02-11 2017-03-15 Beijing Advaccine Biotechnology Co. Ltd. Vaccines with interleukin-17 as an adjuvant
WO2016044189A1 (en) 2014-09-15 2016-03-24 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists
CN107074952B (zh) 2014-09-30 2021-04-09 英特维特国际股份有限公司 结合犬pd-l1的pd-l1抗体
EP3842453A1 (en) 2014-11-06 2021-06-30 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn- and protein a-binding properties
TWI719970B (zh) 2015-03-23 2021-03-01 美商永斯醫療股份有限公司 針對ｉｃｏｓ之抗體
WO2017068472A1 (en) 2015-10-19 2017-04-27 Novartis Ag Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
EP3390451B1 (en) 2015-12-18 2025-01-22 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
AU2017212534A1 (en) 2016-01-26 2018-07-26 Defensin Therapeutics Aps Methods for modulating intestinal microbiota
AU2017219596B2 (en) 2016-02-18 2019-07-04 Elanco Us Inc. Chimeric canine anti-CD20 antibody
US12281154B2 (en) 2016-05-20 2025-04-22 President And Fellows Of Harvard College Gene therapy methods for age-related diseases and conditions
CN110267674A (zh) 2016-07-08 2019-09-20 奥美药业有限公司 包含瘦素的融合蛋白及其生产和使用方法
CN110114369A (zh) 2016-10-17 2019-08-09 威隆股份公司 修饰的抗体恒定区
EP3548073A4 (en) 2016-12-02 2020-07-22 The Texas A&M University System FUSION PROTEINS FOR THE SELECTIVE DEPREVIRANT OF ANTIBODIES SPECIFIC TO AN ANTIGEN
AU2018254542B2 (en) * 2017-04-21 2022-12-22 Elanco Us Inc. IL4/IL13 receptor molecule for veterinary use
CA3065553A1 (en) 2017-06-18 2018-12-27 Kindred Biosciences, Inc. Il17a antibodies and antagonists for veterinary use
WO2019035010A1 (en) 2017-08-15 2019-02-21 Kindred Biosciences, Inc. IGG VARIANTS FOR VETERINARY USE
SI4186920T1 (sl) 2018-06-29 2024-05-31 Akston Biosciences Corporation Ultra dolgo delujoči inzulin-FC fuzijski proteini in postopki uporabe
AU2019338602A1 (en) 2018-09-14 2021-04-01 Elanco Us Inc. Anti-IL4 receptor antibodies for veterinary use
MX2021004313A (es) 2018-10-18 2021-05-27 Kindred Biosciences Inc Variantes de fc con union alterada al receptor de fc neonatal (fcrn) para uso veterinario.
EP3870601A4 (en) 2018-10-25 2022-07-13 Kindred Biosciences, Inc. IL4/IL13 RECEPTOR MOLECULE FOR USE IN VETERINARY MEDICINE
CN113227134A (zh) 2018-12-05 2021-08-06 株式会社梅花治疗 抗体的Fc区变体
AU2019397516A1 (en) 2018-12-12 2021-06-17 Elanco Us Inc. Erythropoietin analogs for veterinary use
US20220064263A1 (en) 2018-12-27 2022-03-03 Kindred Biosciences, Inc. IGG FC Variants for Veterinary Use
US11542333B2 (en) 2019-01-03 2023-01-03 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
BR112021018156A2 (pt) 2019-03-20 2021-11-16 Kindred Biosciences Inc Antagonistas de ngf para uso médico
MX2022002171A (es) 2019-08-22 2022-05-13 Cidara Therapeutics Inc Dominios fc variantes y usos de estos.
CN114364796B (zh) 2019-09-02 2023-07-11 甘李药业股份有限公司 嵌合蛋白
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
MX2022012866A (es) 2020-04-17 2022-11-08 Zoetis Services Llc Variantes de anticuerpos caninos.
MX2022012793A (es) 2020-04-17 2022-11-07 Zoetis Services Llc Variantes de anticuerpos felinos.
CA3173864A1 (en) 2020-04-22 2021-10-28 Shyr Jiann Li Long-acting anti-il31 antibodies for veterinary use
CA3173927A1 (en) 2020-04-22 2021-10-28 Shyr Jiann Li Il4/il13 receptor molecules for veterinary use
CN115867572B (zh) 2020-05-11 2025-06-06 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物和使用方法
EP4166574A4 (en) 2020-06-10 2025-01-15 Bica Therapeutics Inc. FUSION PROTEIN WITH ERYTHROPOIETIN POLYPEPTIDE
EP4172193A1 (en) 2020-06-29 2023-05-03 Zoetis Services LLC Feline antibody variants for improving stability
EP4178977A1 (en) 2020-07-10 2023-05-17 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in felines and methods of use
WO2022046941A1 (en) 2020-08-26 2022-03-03 Angiex, Inc. Antimitotic tetrapeptide-antibody conjugates and methods of using same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090181912A1 (en) * 2005-07-27 2009-07-16 Qinghua Wang GLP/1/EXENDIN 4 IgG Fc FUSION CONSTRUCTS FOR TREATMENT OF DIABETES
JP2010533197A (ja) * 2007-07-10 2010-10-21 イーライ リリー アンド カンパニー ＧＬＰ−１−Ｆｃ融合タンパク質配合物
WO2016108654A1 (ko) * 2014-12-31 2016-07-07 주식회사 제넥신 Glp 및 면역글로불린 하이브리드 fc 융합 폴리펩타이드 및 이의 용도

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
IMMUNOGENETICS, vol. Vol.61, p.209-230, JPN6022038064, 2009, ISSN: 0005021855 *
MOLECULAR IMMUNOLOGY, vol. Vol.45, p.818-827, JPN6022038068, 2008, ISSN: 0005021858 *
PROTEIN ENGINEERING, vol. vol.16, p.243-245, JPN6022038066, 2013, ISSN: 0005021854 *
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. vol.157, p.31-41, JPN6022038065, 2014, ISSN: 0005021856 *
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. vol.158, p.214-223, JPN6022038067, 2014, ISSN: 0005021857 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024530036A (ja) * 2021-08-06 2024-08-14 ペットメディックス・リミテッド 抗体Ｆｃバリアント

Also Published As

Publication number Publication date
AU2023226676B2 (en) 2025-05-22
RU2020110584A3 (cg-RX-API-DMAC7.html) 2021-12-15
RU2020110584A (ru) 2021-09-17
EP3668536A4 (en) 2021-05-26
CN119390821A (zh) 2025-02-07
WO2019035010A1 (en) 2019-02-21
US12297272B2 (en) 2025-05-13
CA3071337A1 (en) 2019-02-21
BR112020002871A2 (pt) 2020-07-28
KR20200057701A (ko) 2020-05-26
US20200362034A1 (en) 2020-11-19
AU2018318440A1 (en) 2020-02-13
CN111182915A (zh) 2020-05-19
EP3668536A1 (en) 2020-06-24
AU2025220819A1 (en) 2025-09-25
MX2020001707A (es) 2020-03-20
AU2023226676A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
JP2020531002A (ja) 獣医学用ｉｇｇ ｆｃ変異体
JP6960832B2 (ja) Ｆｇｆ２１突然変異体及びその使用
US8835385B2 (en) FGF21 polypeptides comprising two or more mutations and uses thereof
US20250092115A1 (en) Igg fc variants for veterinary use
KR20220066002A (ko) 의학적 용도의 ngf 길항제
CA2760674A1 (en) Fgf21 mutants and uses thereof
CN103732628A (zh) 多价杂多聚体骨架设计和构建体
JP2016183180A (ja) 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
KR20230005880A (ko) 수의학적 사용을 위한 il4/il13 수용체 분자
KR20250057131A (ko) 수의학 용도를 위한 il4/il13 수용체 분자
RU2814952C2 (ru) ВАРИАНТЫ IgG-FC ДЛЯ ПРИМЕНЕНИЯ В ВЕТЕРИНАРИИ
RU2829812C2 (ru) Антагонисты ngf для медицинского использования
RU2850882C2 (ru) Варианты fc igg для ветеринарного применения
HK40060829A (en) Igg fc variants for veterinary use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210813

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210813

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230313

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230328

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20231124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251107